From the PR: “In December 2023, the Company ent
Post# of 148110
(Total Views: 724)
Posted On: 02/02/2024 2:12:57 PM
From the PR:
“In December 2023, the Company entered a partnership with Albert Einstein College of Medicine and Montefiore Medical Center, located in New York. The Company will be providing leronlimab to support a pre-clinical trial evaluating the efficacy of leronlimab independently and in combination with temozolomide in treating glioblastoma multiforme, also known as grade IV astrocytoma (“GBM”) in infected humanized mice. The study will involve three groups of humanized mice: one control group, one group that will receive only leronlimab, and another group that will receive a combination of leronlimab and temozolomide. The primary objective of this study is to evaluate the effect of leronlimab on the primary tumor growth and occurrence of metastases on CCR5+ and CCR5- cells in humanized mice. Upon completion of the study, the academic institutions will provide the Company with a research report outlining the study results, and they will have the right to publish and present the study results. GBM is the most common type of primary malignant brain tumor and is aggressive and fast-growing. This study is expected to take place in the 2024 calendar year.”
The outcome of this study should be interesting. I’m glad there is a separate arm with Leronlimab alone. Temozolimide, a PARP inhibitor, has been around for ages, does cross the blood brain barrier but does not knock it out the park when it comes to pushing out survival. The overall 5 year survival for GBM is only 4.7%. Median progression free survival on temozolimide is 6.9 months and median overall survival is 14.6 months. The drug methylates DNA, inhibiting repair, leading to apoptosis and cell death but it’s like a bowling ball that doesn’t stay in its lane, capable of taking out rapidly dividing cells elsewhere…your hair falls out and you get nausea and vomiting because these cells have a higher turnover rate. As mentioned Glioblastoma arises from astrocyte’s, which are known to be high CCR5 expressing cells.
Unleash the Kraken, let’s get this drug out there! Let the humanized mice speak, all creatures great and small should have their say but let’s not forget we have ALREADY seen positive results on humans with Glioblastoma in the Leronlimab basket trial.
“In December 2023, the Company entered a partnership with Albert Einstein College of Medicine and Montefiore Medical Center, located in New York. The Company will be providing leronlimab to support a pre-clinical trial evaluating the efficacy of leronlimab independently and in combination with temozolomide in treating glioblastoma multiforme, also known as grade IV astrocytoma (“GBM”) in infected humanized mice. The study will involve three groups of humanized mice: one control group, one group that will receive only leronlimab, and another group that will receive a combination of leronlimab and temozolomide. The primary objective of this study is to evaluate the effect of leronlimab on the primary tumor growth and occurrence of metastases on CCR5+ and CCR5- cells in humanized mice. Upon completion of the study, the academic institutions will provide the Company with a research report outlining the study results, and they will have the right to publish and present the study results. GBM is the most common type of primary malignant brain tumor and is aggressive and fast-growing. This study is expected to take place in the 2024 calendar year.”
The outcome of this study should be interesting. I’m glad there is a separate arm with Leronlimab alone. Temozolimide, a PARP inhibitor, has been around for ages, does cross the blood brain barrier but does not knock it out the park when it comes to pushing out survival. The overall 5 year survival for GBM is only 4.7%. Median progression free survival on temozolimide is 6.9 months and median overall survival is 14.6 months. The drug methylates DNA, inhibiting repair, leading to apoptosis and cell death but it’s like a bowling ball that doesn’t stay in its lane, capable of taking out rapidly dividing cells elsewhere…your hair falls out and you get nausea and vomiting because these cells have a higher turnover rate. As mentioned Glioblastoma arises from astrocyte’s, which are known to be high CCR5 expressing cells.
Unleash the Kraken, let’s get this drug out there! Let the humanized mice speak, all creatures great and small should have their say but let’s not forget we have ALREADY seen positive results on humans with Glioblastoma in the Leronlimab basket trial.
(19)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼